Latest Product Launch News

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Bega Cheese Limited reported a robust FY2025 with a 23% rise in normalised EBITDA to $202 million, underpinned by branded growth and a turnaround in its bulk segment. Strategic manufacturing rationalisation and new product innovation set the stage for continued momentum.

Bega Cheese Limited reported a robust FY2025 with a 23% rise in normalised EBITDA, driven by strong branded product growth and a turnaround in its Bulk segment. The company forecasts further gains in FY2026 with new product launches and operational efficiencies.

Bega Cheese Limited reported a mixed FY2025 with statutory revenue edging up to $3.54 billion but a statutory loss after tax of $8.5 million, offset by a strong normalised profit and a 50% dividend increase. The company is advancing manufacturing rationalisation and sustainability initiatives while expanding internationally.

Elixinol Wellness has launched its Healthy Chef Protein Water range, entering Australia’s rapidly expanding $499 million protein supplements market with a clean-label, functional beverage lineup.

Ainsworth Game Technology reported a steady half-year profit of $4.9 million on a 25% revenue increase, driven by strong domestic sales and new product launches, while navigating regional challenges and a looming Novomatic takeover bid.

Breville Group Limited reported robust FY25 results with double-digit revenue and profit growth, successfully navigating US-China tariff challenges through strategic manufacturing diversification and market expansion.

Breville Group delivers robust FY25 results with double-digit revenue and profit growth, successfully navigating US tariff pressures while expanding globally and investing in manufacturing diversification.

Ainsworth Game Technology reported a robust 25% increase in revenue for the first half of 2025, driven by strong land-based sales and new product launches, but statutory profit plunged 65% due to foreign exchange losses and one-off transaction costs. The company’s strategic acquisition by Novomatic advances as shareholder approval looms.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Judo Capital Holdings delivered a robust FY25 with strong loan and deposit growth, improved profitability, and a strategic technology upgrade, setting the stage for ambitious FY26 targets.